Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals PLC reported promising Phase 1 clinical trial results for MTX110 in treating Diffuse Midline Glioma, a rare pediatric brain cancer, with patients showing a median overall survival of 16.5 months compared to the historical 10 months. The treatment, which is delivered directly to the tumor site, was generally well tolerated, with most adverse events being infusion-related and non-severe. These results, presented at ISPNO 2024, may represent a significant step forward in the management of this aggressive cancer.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
